• Je něco špatně v tomto záznamu ?

Superior role of waist circumference to body-mass index in the prediction of cardiometabolic risk in dyslipidemic patients

Ľ. Cibičková, K. Langová, H. Vaverková, J. Lukeš, N. Cibiček, D. Karásek

. 2019 ; 68 (6) : 931-938. [pub] 20191025

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20010280

Coronary risk evaluation by conventional factors (age, gender, smoking, blood pressure and cholesterol) may further be specified by facets of the metabolic syndrome, namely insulin resistance, hypertriglyceridemia and obesity. Although obesity is usually defined as elevated body mass index (BMI), recent data indicate a superior role of waist circumference or hypertri-glyceridemic waist (HTGW) over BMI in the assessment of cardiometabolic risk. In dyslipidemic patients, the specific contributions of risky waist, HTGW or BMI have not been evaluated as yet. 686 dyslipidemic subjects (322 males and 364 females) were enrolled into a cross-sectional study. In each subject basic antropometry (i.e. waist circumference, HTGW, BMI) and laboratory parameters of lipid profile and insulin resistance were determined. Cardiometabolic risk was given by fulfilling the criteria (harmonized definition) of metabolic syndrome. The significance of risky waist, HTGW and BMI were assessed by comparing the respective predictive values for the presence of metabolic syndrome. Dyslipidemic patients with risky waist, HTGW or high BMI have a more atherogenic lipid profile and higher insulin resistance compared to those without risky waist, HTGW or high BMI. Risky waist is stronger predictor of metabolic syndrome (PPV 66 %, NPV 90 %) and thus posesa greater cardiometabolic risk than higher BMI per se does (PPV 42 %, NPV 97 %). The contribution of triglycerides (i.e. HTGW) to these predictive values is marginal (PPV 66 %, NPV 92 %). The present results highlight the superior role of waist circumference as a screening tool over BMI for the evaluation of cardiometabolic risk in dyslipidemic subjects. HTGW brings little additional benefit in risk stratification. Lower BMI proved to be optimal for identifying the subjects with inferior risk.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc20010280
003      
CZ-PrNML
005      
20200720141433.0
007      
ta
008      
200707s2019 xr f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934176 $2 doi
035    __
$a (PubMed)31647298
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Cibičková, Ľubica $7 xx0224082 $u Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, University Hospital, Olomouc, Czech Republic
245    10
$a Superior role of waist circumference to body-mass index in the prediction of cardiometabolic risk in dyslipidemic patients / $c Ľ. Cibičková, K. Langová, H. Vaverková, J. Lukeš, N. Cibiček, D. Karásek
504    __
$a Literatura
520    9_
$a Coronary risk evaluation by conventional factors (age, gender, smoking, blood pressure and cholesterol) may further be specified by facets of the metabolic syndrome, namely insulin resistance, hypertriglyceridemia and obesity. Although obesity is usually defined as elevated body mass index (BMI), recent data indicate a superior role of waist circumference or hypertri-glyceridemic waist (HTGW) over BMI in the assessment of cardiometabolic risk. In dyslipidemic patients, the specific contributions of risky waist, HTGW or BMI have not been evaluated as yet. 686 dyslipidemic subjects (322 males and 364 females) were enrolled into a cross-sectional study. In each subject basic antropometry (i.e. waist circumference, HTGW, BMI) and laboratory parameters of lipid profile and insulin resistance were determined. Cardiometabolic risk was given by fulfilling the criteria (harmonized definition) of metabolic syndrome. The significance of risky waist, HTGW and BMI were assessed by comparing the respective predictive values for the presence of metabolic syndrome. Dyslipidemic patients with risky waist, HTGW or high BMI have a more atherogenic lipid profile and higher insulin resistance compared to those without risky waist, HTGW or high BMI. Risky waist is stronger predictor of metabolic syndrome (PPV 66 %, NPV 90 %) and thus posesa greater cardiometabolic risk than higher BMI per se does (PPV 42 %, NPV 97 %). The contribution of triglycerides (i.e. HTGW) to these predictive values is marginal (PPV 66 %, NPV 92 %). The present results highlight the superior role of waist circumference as a screening tool over BMI for the evaluation of cardiometabolic risk in dyslipidemic subjects. HTGW brings little additional benefit in risk stratification. Lower BMI proved to be optimal for identifying the subjects with inferior risk.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a index tělesné hmotnosti $7 D015992
650    _2
$a kardiovaskulární nemoci $x krev $x diagnóza $x epidemiologie $7 D002318
650    _2
$a průřezové studie $7 D003430
650    _2
$a dyslipidemie $x krev $x diagnóza $x epidemiologie $7 D050171
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metabolický syndrom $x krev $x diagnóza $x epidemiologie $7 D024821
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a rizikové faktory $7 D012307
650    _2
$a obvod pasu $x fyziologie $7 D055105
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Langová, Kateřina $7 xx0141371 $u Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
700    1_
$a Vaverková, Helena, $d 1942- $7 nlk20000083882 $u Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, University Hospital, Olomouc, Czech Republic
700    1_
$a Lukeš, Jiří $7 xx0070976 $u Department of Clinical Biochemistry, University Hospital, Olomouc, Czech Republic
700    1_
$a Cibiček, Norbert, $d 1978- $7 xx0149269 $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
700    1_
$a Karásek, David $7 stk2007415300 $u Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, University Hospital, Olomouc, Czech Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 68, č. 6 (2019), s. 931-938
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31647298 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20200707 $b ABA008
991    __
$a 20200709143024 $b ABA008
999    __
$a ok $b bmc $g 1545939 $s 1100372
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 68 $c 6 $d 931-938 $e 20191025 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20200707

Najít záznam

Citační ukazatele

Možnosti archivace